2020年美国癌症统计报告
美国癌症协会估算2020年美国新发癌症1,806,590例、死亡606,520例;下降主要由肺癌、结直肠癌、乳腺癌和前列腺癌驱动,但近十年乳腺癌和结直肠癌下降放缓、前列腺癌停滞,肺癌下降加速。
要点
- 2020年美国预计新发癌症1,806,590例,癌症死亡606,520例。
- 2008-2017年肺癌死亡率下降加速,男性年降幅从3%增至5%,女性从2%增至近4%。
核心结论
- 部分可早期检测的癌症下降势头放缓,而其他常见癌症取得显著进展。
研究设计与样本
- 美国癌症协会年度统计报告,基于人群的癌症发病与死亡数据。
- 发病数据截至2016年,来自SEER、NPCR和NAACCR;死亡数据截至2017年,来自NCHS。
主要发现
- 2020年美国预计新发癌症1,806,590例,癌症死亡606,520例。
- 2008-2017年女性乳腺癌和结直肠癌死亡率下降放缓,前列腺癌下降停滞。
- 2008-2013年至2013-2017年,男性肺癌死亡率年降幅从3%加速至5%,女性从2%加速至近4%。
- 2016至2017年总体癌症死亡率单年下降2.2%,为历史最大单年降幅。
- 2017年肺癌死亡人数仍超过乳腺癌、前列腺癌、结直肠癌和脑癌死亡人数之和。
关键数值与推荐
- 2013-2017年男性肺癌死亡率年降5%,女性年降近4%;2008-2013年分别为3%和2%。
- 2016至2017年总体癌症死亡率单年下降2.2%。
- 50-64岁人群皮肤黑色素瘤死亡率年降幅从2006-2010年的1%增至2013-2017年的7%,20-49岁人群从2%增至3%。
- 65岁及以上人群黑色素瘤死亡率2013-2017年年降5%至6%,而2013年前该年龄组死亡率在上升。
临床怎么用
- 关注肺癌死亡率下降加速的趋势,可能反映治疗与控烟的综合效果。
- 乳腺癌和结直肠癌筛查与治疗进展带来的死亡率下降近十年放缓,需持续优化早诊早治。
- 前列腺癌死亡率下降停滞,提示需重新审视筛查与治疗策略。
- 黑色素瘤新疗法获批后死亡率下降显著,支持转移性疾病新疗法的应用。
局限性
- 发病数据截至2016年,死亡数据截至2017年,结论反映历史趋势而非实时情况。
- 为基于人群的估算与统计描述,未报告因果推断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States and compiles the most recent data on population-based cancer occurrence. Incidence data (through 2016) were collected by the Surveillance, Epidemiology, and End Results Program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries. Mortality data (through 2017) were collected by the National Center for Health Statistics. In 2020, 1,806,590 new cancer cases and 606,520 cancer deaths are projected to occur in the United States. The cancer death rate rose until 1991, then fell continuously through 2017, resulting in an overall decline of 29% that translates into an estimated 2.9 million fewer cancer deaths than would have occurred if peak rates had persisted. This progress is driven by long-term declines in death rates for the 4 leading cancers (lung, colorectal, breast, prostate); however, over the past decade (2008-2017), reductions slowed for female breast and colorectal cancers, and halted for prostate cancer. In contrast, declines accelerated for lung cancer, from 3% annually during 2008 through 2013 to 5% during 2013 through 2017 in men and from 2% to almost 4% in women, spurring the largest ever single-year drop in overall cancer mortality of 2.2% from 2016 to 2017. Yet lung cancer still caused more deaths in 2017 than breast, prostate, colorectal, and brain cancers combined. Recent mortality declines were also dramatic for melanoma of the skin in the wake of US Food and Drug Administration approval of new therapies for metastatic disease, escalating to 7% annually during 2013 through 2017 from 1% during 2006 through 2010 in men and women aged 50 to 64 years and from 2% to 3% in those aged 20 to 49 years; annual declines of 5% to 6% in individuals aged 65 years and older are particularly striking because rates in this age group were increasing prior to 2013. It is also notable that long-term rapid increases in liver cancer mortality have attenuated in women and stabilized in men. In summary, slowing momentum for some cancers amenable to early detection is juxtaposed with notable gains for other common cancers.
引用
- Siegel RL, Miller KD, Jemal A, et al. Cancer statistics, 2020. CA Cancer J Clin. 2020. PMID: 31912902. doi:10.3322/caac.21590
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。